RenovoRx, Inc. (RNXT)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1574094 · fiscal year ends in Dec
Closing price $1.33 on 30 Oct 2026; 52-week range $0.73 to $2.52.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $2.0M
- Net income, last twelve months
- -$12.3M
- Earnings per share
- -$0.31
- Gross margin
- 84.4%
- Operating margin
- -685.2%
- Net margin
- -621.7%
- Free cash flow
- -$11.9M
- Return on equity
- -136.8%
- Market value
- $60.2M
- Cash
- $9.5M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 45.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $1.1M | -$12.5M | -$11.2M | -$0.32 | -$11.0M | 10-K filed 30 Mar 2026 |
| FY2024 | 31 Dec 2024 | $43.0K | -$11.0M | -$8.8M | -$0.40 | -$9.1M | 10-K filed 1 Apr 2025 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $909.0K | -$2.9M | -$0.06 |
| Q1 FY2026 | 31 Mar 2026 | $563.0K | -$3.5M | -$0.09 |
| Q4 FY2025 | 31 Dec 2025 | $238.0K | -$2.9M | -$0.08 |
| Q3 FY2025 | 30 Sep 2025 | $266.0K | -$2.9M | -$0.08 |
| Q2 FY2025 | 30 Jun 2025 | $422.0K | -$2.9M | -$0.08 |
| Q1 FY2025 | 31 Mar 2025 | $197.0K | -$2.4M | -$0.08 |
Company events
The newest 8-K filings of 55 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 20 Aug 2026 | 8-K | Other events | 8.01 |
| 13 Aug 2026 | 8-K/A | Results | 2.02, 9.01 |
| 4 Aug 2026 | 8-K | Other events | 8.01, 9.01 |
| 2 Jul 2026 | 8-K | Delisting notice | 3.01 |
| 30 Jun 2026 | 8-K | Shareholder vote | 5.07, 9.01 |
| 14 May 2026 | 8-K | Results | 2.02, 9.01 |
| 30 Mar 2026 | 8-K | Results, Other events | 2.02, 8.01, 9.01 |
| 27 Mar 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 23 Mar 2026 | 8-K | Material agreement, Share sale, Other events | 1.01, 3.02, 8.01, 9.01 |
| 6 Feb 2026 | 8-K | Leadership change, Other events | 5.02, 8.01, 9.01 |
| 2 Jan 2026 | 8-K | Delisting notice | 3.01 |
| 14 Nov 2025 | 8-K | Material agreement | 1.01, 9.01 |
Every filing
The newest filings with the SEC of 157 held.
| Filed | Form | Period |
|---|---|---|
| 16 Oct 2026 | RW | – |
| 20 Aug 2026 | 8-K | 20 Aug 2026 |
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 13 Aug 2026 | 8-K/A | 12 Aug 2026 |
| 12 Aug 2026 | 8-K | 12 Aug 2026 |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 2 Jul 2026 | 8-K | 1 Jul 2026 |
| 30 Jun 2026 | S-8 | – |
| 30 Jun 2026 | 8-K | 30 Jun 2026 |
| 15 May 2026 | 10-K/A | 31 Dec 2025 |
| 14 May 2026 | 10-Q | 31 Mar 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 19 May 2026 | Voll Mark, Chief Financial Officer | Purchase | 25,000 | $0.79 | $19.7K | 142,380 | 21 May 2026 |
| 20 Mar 2026 | Marton Laurence, Director | Purchase | 9,720 | – | $0 | 9,720 | 24 Mar 2026 |
| 20 Mar 2026 | Bagai Shaun, Chief Executive Officer | Purchase | 24,300 | – | $0 | 313,357 | 24 Mar 2026 |
| 20 Mar 2026 | Voll Mark, Chief Financial Officer | Purchase | 97,200 | – | $0 | 97,200 | 24 Mar 2026 |
| 21 Jan 2026 | Agah Ramtin, Chief Medical Officer | Purchase | 10,000 | $1.00 | $10.0K | 798,460 | 22 Jan 2026 |
| 31 Dec 2025 | Agah Ramtin, Chief Medical Officer | Purchase | 9,795 | $0.86 | $8.4K | 788,460 | 5 Jan 2026 |
| 30 Dec 2025 | Agah Ramtin, Chief Medical Officer | Purchase | 205 | $0.83 | $169 | 778,665 | 2 Jan 2026 |
| 18 Dec 2025 | Bagai Shaun, Chief Executive Officer | Purchase | 5,000 | $0.90 | $4.5K | 340,040 | 22 Dec 2025 |
| 17 Dec 2025 | Bagai Shaun, Chief Executive Officer | Purchase | 5,000 | $0.85 | $4.3K | 335,040 | 19 Dec 2025 |
| 16 Dec 2025 | Agah Ramtin, Chief Medical Officer | Purchase | 12,000 | $0.85 | $10.2K | 778,460 | 17 Dec 2025 |
| 5 Dec 2025 | Agah Ramtin, Chief Medical Officer | Purchase | 10,000 | $0.96 | $9.6K | 766,460 | 8 Dec 2025 |
| 24 Nov 2025 | Agah Ramtin, Chief Medical Officer | Purchase | 12,000 | $0.80 | $9.6K | 756,460 | 24 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Apr 2026 | Orin Hirschman | 13G amended | 9.8% | 4.4M |
| 30 Jan 2026 | Orin Hirschman | 13G amended | 7.1% | 2.6M |
| 13 Nov 2025 | AWM Investment Company, Inc. | 13G amended | 2.4% | 863.8K |
| 10 Nov 2025 | Orin Hirschman | 13G amended | 7.1% | 2.6M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 864.6K | -8.7% | 1.64 |
| 30 Sep 2026 | 947.0K | +40.59% | 1.59 |
| 15 Sep 2026 | 673.6K | +55.65% | 1 |
| 31 Aug 2026 | 432.7K | -35.8% | 1 |
| 14 Aug 2026 | 674.0K | +137.8% | 1.22 |
| 31 Jul 2026 | 283.4K | -13.55% | 1.44 |
| 15 Jul 2026 | 327.9K | -5.19% | 1.68 |
| 30 Jun 2026 | 345.8K | -0.98% | 1.4 |
Funds that hold it
From each fund's latest Form 13F.
34 funds held it at 30 Jun 2026: 11 added and 6 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| AIGH Capital Management LLC | 4,405,439 | $4.3M | +699,242 |
| Bleichroeder LP | 1,666,098 | $1.6M | 0 |
| Vanguard Capital Management LLC | 1,443,742 | $1.4M | -3,435 |
| Geode Capital Management, LLC | 424,148 | $415.7K | +42,425 |
| Wealthspire Advisors, LLC | 252,525 | $247.5K | 0 |
| Vanguard Fiduciary Trust Co. | 240,330 | $235.5K | +82,428 |
| Citadel Advisors LLC | 133,597 | $130.9K | -99,087 |
| Northern Trust Corp. | 85,207 | $83.5K | +43,046 |
| Chicago Partners Investment Group LLC | 92,356 | $78.9K | 0 |
| Northwestern Mutual Wealth Management Co. | 74,596 | $73.1K | -24,864 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B